Diabetes and hypertension, the deadly duet: Importance, therapeutic strategy, and selection of drug therapy

Cardiology Clinics

Volumn 23, Issue 2, 2005, Pages 139-152

  Deedwania, Prakash C ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ATENOLOL; BENAZEPRIL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; FOSINOPRIL; HYDRALAZINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; NISOLDIPINE; PRAZOSIN; PROPRANOLOL; RECOMBINANT HUMAN INSULIN; RESERPINE; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; TRANDOLAPRIL PLUS VERAPAMIL; UNINDEXED DRUG; VALSARTAN;

BLOOD GLUCOSE MONITORING; BLOOD PRESSURE MONITORING; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG CHOICE; DRUG COST; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY FAILURE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT;

EID: 13444270669     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2004.06.006     Document Type: Review

References (88)

1. J. Herlitz How to improve the cardiac prognosis for diabetes Diabetes Care 22 Suppl 2 1999 B89 B96
2. T.C. Fagan, and P.C. Deedwania The cardiovascular dysmetabolic syndrome Am J Med 105 1A 1998 77S 82S
3. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 BMJ 317 1998 703 713
4. UK Prospective Diabetes Study Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
5. UK Prospective Diabetes Study Group Efficacy of atenolol and captopril in reducing risk of both macrovascular and microvascular complications in type 2 diabetes (UKPDS 39) BMJ 317 1998 713 720
6. S.M. Haffner Epidemiology of type 2 diabetes: risk factors Diabetes Care 21 Suppl 3 1998 C3 C6
7. L. Tarnow, P. Rossing, and M.-A Gall Prevalence of arterial hypertension in diabetic patients before and after the JNC-V Diabetes Care 17 1994 1247 1251
8. Hypertension in diabetes study (HDS). I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications J Hypertension 11 1993 309 317
9. V.L. Burt, P. Whelton, and E.J. Roccella Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-91 Hypertension 25 1995 305 313
10. F. DeStafano, E.S. Ford, J. Newman, J.M. Stevenson, S.F. Wetterhall, and R.F. Anda Risk factors for coronary heart disease mortality among persons with diabetes Ann Epidemiol 3 1993 27 34
11. M.H. Criqui Epidemiology of atherosclerosis: an updated overview Am J Cardiol 57 1986 18C 23C
12. P.W. Wilson An epidemiologic perspective of systemic hypertension, ischemic heart disease, and heart failure. Framingham Heart Study Am J Cardiol 80 9B 1997 3J 8J
13. The National High Blood Pressure Education Program Working Group National High Blood Pressure Education Program Working Group report on hypertension in diabetes Hypertension 23 1994 145 158
14. Systolic hypertension in Europe trial investigators Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension N Engl J Med 340 1999 677 684
15. E. Ritz, I. Rychlik, F. Locatelli, and S. Halimi End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions Am J Kidney Dis 34 1999 795 808
16. Cost effectiveness of intensive treatment of hypertension. Based on presentations by Donald S. Shepard, PhD and Dominic Hodgkin, PhD Am J Manag Care 4 12 Suppl 1998 S765 S769 [discussion S770]
17. UK Prospective Diabetes Study Group Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40 BMJ 317 7160 1998 720 726 12
18. W.J. Elliott, D.R. Weir, and H.R. Black Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Arch Intern Med 160 9 2000 1277 1283 8
19. The Sixth Report of The Joint National Committee on Prevention Detection, Evaluation, and Treatment of High Blood Pressure Arch Intern Med 157 1997 2413 2446
20. M. Prencipe, A.R. Casini, M. Santini, C. Ferretti, N. Scaldaferri, and F. Culasso Prevalence, awareness, treatment and control of hypertension in the elderly: results from a population survey J Hum Hypertens 14 2000 825 830
21. S.E. Kjeldsen, B. Dahlof, R.B. Devereux, S. Julius, U. de Faire, and F. Fyhrquist Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Am J Hypertens 13 2000 899 906
22. American Diabetes Association. Position statement: treatment of hypertension in adults with diabetes. 2002;25:571-3.
23. 1999 Canadian recommendations for the management of hypertension CMAJ 161 12 Suppl 1999 S1 S17
24. J.V. Gainer, J.D. Morrow, A. Loveland, D.J. King, and N.J. Brown Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects N Engl J Med 339 1998 1285 1292
25. J.M. Wright Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 2: Beta-blockers CMAJ 163 2 2000 188 192
26. L. Hansson, L.H. Lindholm, L. Niskanen, J. Lanke, and T. Hendner Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial Lancet 353 1999 611 616
27. The Heart Outcomes Prevention Evaluation Study Investigators Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients N Engl J Med 342 2000 145 153
28. F. Galletti, P. Strazzullo, B. Capaldo, R. Carretta, F. Fabris, and L.A. Ferrara Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: Trandolapril Italian Study (TRIS) J Hypertens 17 1999 439 445
29. G.K. Buller, and M. Perazella ACE inhibitor-induced hypoglycaemia Am J Med 91 1991 104 105
30. Heart Outcomes Prevention Evaluation (HOPE) study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy Lancet 355 2000 253 259
31. L.C. Reardon, and D.S. Macpherson Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med 158 1 1998 26 32 12
32. T.L. Goodfriend, M.E. Elliott, and K.J. Catt Drug therapy: angiotensin receptors and their antagonists N Engl J Med 334 1996 1649 1654
33. J.M. Wright Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 3: Angiotensin-converting-enzyme, ACE inhibitors CMAJ 163 2000 293 296
34. R.W. Piepho Overview of the angiotensin-converting-enzyme inhibitors Am J Health Syst Pharm 57 Suppl 1 2001 S3 S7
35. K.K. Warner, J.A. Visconti, and M.M. Tschampel Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema Ann Pharmacother 34 2000 526 528
36. E. Grossman Angiotensin II receptor blockers Arch Intern Med 160 2000 1905 1911
37. G.L. Bakris, M. Siomos, D. Richardson, I. Janssen, W.K. Bolton, and L. Hebert ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure Kidney Int 58 2000 2084 2092
38. S. Shah, I. Khatri, and E.D. Freis Mechanism of antihypertensive effect of thiazide diuretics Am Heart J 95 5 1978 611 618
39. P.O. Weidmann, L. Boehlen, and M. de Courten Pathogenesis and treatment of hypertension associated with diabetes mellitus Am Heart J 125 1993 1498 1513
40. Systolic Hypertension in the Elderly Program Cooperative Research Group Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension JAMA 276 1996 1886 1892
41. J.B. Kostis, K.G. Berge, B.R. Davis, C.M. Hawkins, and J. Probstfield Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP) Am J Hypertens 8 12 Pt 1 1995 1147 1153
42. J. Warram, L.M. Laffel, and P. Valsania Excess mortality associated with diuretic therapy in diabetes mellitus Arch Intern Med 151 1991 1350 1356
43. S. David, T.E. Siscovick, B.M. Raghunathan, T.D. Psaty, K.G. Koepsell, and X.L. Wicklund Diuretic Therapy for Hypertension and the Risk of Primary Cardiac Arrest N Engl J Med 330 1994 1852 1857
44. G. Zuanetti, and R. Latini Impact of pharmacological treatment on mortality after myocardial infarction in diabetic patients J Diabet Complications 11 1997 131 136
45. T.W. Gress, J. Nieto, I. Shahar, and F.L. Brancati Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. For the atherosclerosis risk in communities study N Engl J Med 342 2000 905 912
46. Veterans Administration Cooperative Study Group on Antihypertensive Agents Propranolol or hydrochlorothiazide alone for the initial treatment of hypertension. IV. Effect on plasma glucose and glucose tolerance Hypertension 7 1985 1008 1016
47. M. Ravid, D. Brosh, Z. Levi, and Y. Bar-Dayan Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial Ann Intern Med 128 1998 982 988
48. S.P. Deacon, and D. Barnett Comparison of atenolol and propranolol during insulin-induced hypoglycaemia BMJ 2 1976 272 273
49. D. Kerr, I.A. Macdonald, and S.R. Heller Beta-adrenoceptor blockade and hypoglycaema Br J Clin Pharmacol 29 1990 685 693
50. I.B. Hirsch, P.J. Boyle, S. Craft, and P.E. Cryer Higher glycemic thresholds for symptoms during beta-adrenergic blockade in IDDM Diabetes 40 9 1991 1177 1186
51. J. Lyngsoe, M. Sorensen, and H. Sjostrand The effect of sustained release verapamil on glucose metabolism in patients with NIDDM Drugs 1 1992 85 87
52. L. Hansson, A. Zanchetti, and S.G. Carruthers Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial Lancet 351 1998 1755 1762
53. R.O. Estacio, B.W. Jeffers, and W.R. Hiatt The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension N Engl J Med 338 1998 645 652
54. P. Tatti, M. Pahor, and R. Byington Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM Diabetes Care 21 1998 597 603
55. F.H. Messerli, S. Oparil, and Z. Feng Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension Am J Cardiol 86 2000 1182 1187
56. H.O. Lithell Hyperinsulinemia, insulin resistance, and the treatment of hypertension Am J Hypertens 9 1996 150S 154S
57. P. Andersen, I. Seljeflot, and A. Herzog Effects of doxazosin and atenolol on atherothrombogenic risk profile in hypertensive middle-age men J Cardiovasc Pharmacol 31 1998 677 683
58. The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone JAMA 283 2000 1967 1975
59. J.H. Bauer, L.B. Jones, and P. Gaddy Effects of prazosin therapy on blood pressure, renal function, and body fluid composition Arch Intern Med 114 1984 1196 1200
60. F.H.H. Leenen, D.L. Smith, R.M. Faraks, R.A. Reeves, and A. Marquez-Julio Vasodilators and regression of left ventricular hypertrophy: hydralazine versus prazosin in hypertensive patients Am J Med 82 1987 969 978
61. P.R. Liebson, G.A. Grandits, and S. Dianzumba Comparison of 5 antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the treatment of mild hypertension study Circulation 91 1995 698 706
62. J.S. Gottdiener, D.J. Reda, and B.M. Massie Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents Circulation 95 1997 2007 2014
63. Y. Liao, and A. Husain The chymase-angiotensin system in humans: biochemistry, molecular biology and potential role in cardiovascular diseases Can J Cardiol 11 Suppl F 1995 13F 19F
64. C.E. Mogensen, S. Neldam, I. Tikkanen, S. Oren, R. Viskoper, and R.W. Watts Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study BMJ 321 7274 2000 1440 1444
65. Y. Lacourciere, A. Belanger, C. Godin, J.P. Halle, S. Ross, and N. Wright Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy Kidney Int 58 2 2000 762 769
66. M. Pohl, M. Cooper, J. Ulrey, J. Pauls, and R. Rohse Safety and efficacy of irbesartan in hypertensive patients with type 2 diabetes and proteinuria [abstract] Am J Hypertens 10 1997 105A
67. L.H. Lindholm, L. Hansson, T. Ekbom, B. Dahlof, J. Lanke, and E. Linjer Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group J Hypertens 18 11 2000 1671 1675
68. L. Hansson, L.H. Lindholm, T. Ekbom, B. Dahlöf, J. Lanke, and B. Scherstén et al., for the STOP-Hypertension-2 study group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study Lancet 354 1999 1751 1756
69. L. Hansson, T. Hedner, P. Lund-Johansen, S.E. Kjeldsen, L.H. Lindholm, and J.O. Syvertsen for the NORDIL Study Group Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study Lancet 356 2000 359 365
70. M.J. Brown, C.R. Palmer, A. Castaigne, P.W. de Leeuw, G. Mancia, and T. Rosenthal Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) Lancet 356 2000 366 372
71. E.J. Lewis, L.G. Hunsicker, R.P. Bain, and R.D. Rohde The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy N Engl J Med 329 1993 1456 1462
72. M. Ravid, D. Broth, Z. Levi, and Y. Bar-Dayan Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial Ann Intern Med 128 1998 982 988
73. C.E. Mogensen Renoprotective role of ACE inhibitors in diabetic nephropathy Br Heart J 72 3 Suppl 1994 S38 S45
74. M. Ruddy Angiotensin II receptor blockade in diabetic nephropathy Am J Hypertens 15 2002 466
75. R.O. Estacio, B.W. Jeffers, N. Gifford, and R.W. Dchrier Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes Diabetes Care 23 Suppl 2 2000 B54 B64
76. J.C. Peterson, S. Adler, and J.M. Burkart Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study Ann Intern Med 123 1995 754 762
77. J.M. Lazarus, J.J. Bourgoignie, and V.M. Buckalew for the Modification of Diet in Renal Disease Study Group Achievement and safety of low blood pressure goal in chronic renal disease: the Modification of Diet in Renal Disease Study Group Hypertension 29 1997 641 650
78. T.F. Luscher, and B. Waeber Efficacy and safety of various combination therapies based on a calcium antagonist in essential hypertension: results of a placebo-controlled randomized trial J Cardiovasc Pharmacol 21 2 1993 305 309
79. D.B. Pittrow, A. Antlsperger, D. Welzel, G. Wambach, W. Schardt, and G. Weidinger Evaluation of the efficacy and tolerability of a low-dose combination of isradipine and spirapril in the first-line treatment of mild to moderate essential hypertension Cardiovasc Drugs Ther 11 5 1997 619 627
80. F. Plat, and R. Saini Management of hypertension: the role of combination therapy Am J Hypertens 10 10 Pt 2 1997 262S 271S
81. J.S. Corcoran, J.E. Perkins, B.I. Hoffbrand, and J.S. Yudkin Treating hypertension in non-insulin-dependent diabetes: a comparison of atenolol, nifedipine, and captopril combined with bendrofluazide Diabet Med 4 2 1987 164 168
82. T. Shigihara, A. Sato, K. Hayashi, and T. Saruta Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalbuminuric patients with type II diabetes Hypertens Res 23 3 2000 219 226
83. G.L. Bakris, M.R. Weir, V. DeQuattro, and F.G. McMahon Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy Kidney Int 54 4 1998 1283 1289
84. A. Souviron Rodriguez, and M. Martinez Morillo Captopril + hydrochlorothiazide versus captopril + nifedipine in the treatment of arterial hypertension in diabetes mellitus type II [abstract] Rev Esp Cardiol 45 7 1992 432 437 [in Spanish]
85. M. Schneider, M. Lerch, M. Papiri, P. Buechel, L. Boehlen, and S. Shaw Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlortali done treatment in hypertensive type 2 diabetes J Hypertens 14 5 1996 669 677
86. G.R. Sheinfeld, and G.L. Bakris Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients Am J Hypertens 12 8 pt 2 1999 80S 85S
87. J. Stamler, O. Vaccaro, J.D. Neaton, and D. Wentworth Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial Diabetes Care 16 1993 434 444
88. A. Sniderman, C. Michel, and N. Racine Heart disease in patients with diabetes mellitus J Clin Epidemiol 45 1992 1357 1370